Abstract:Objective. The aims of this study were to investigate the impact of TAK-242 on the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear transcription factor-κB (NF-κB) signal transduction pathway in rats with hepatic fibrosis (HF) using the liver gut axis and to investigate the molecular mechanism of its intervention on HF. Methods. SPF grade SD male rats were randomly allocated to the control, model, and TAK-242 groups. For 8 weeks, the model and TAK-242 groups received 3 mL·kg-1 (the initial dose 5 mL·kg-1) intraperitoneal injections of 40% CCL4 olive oil solution. TAK-242 (5 mg·kg-1) was administered once a day for 5 days after modeling. The pathological alterations of liver and small intestine tissues in each group were observed using H&E and Masson staining. ELISA was used to measure serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DBIL), total bilirubin (TBIL), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). RT-qPCR was utilized to identify the mRNA expression level of IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB in rat liver and small intestine tissues. The protein level of IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB protein in rat liver and small intestine tissues was determined utilizing Western blot and IHC. Results. TAK-242 significantly reduced AST, ALT, TBIL, and DBIL expression in HF rats' serum ( P < 0.01 ) and alleviated liver tissue injury. Hematoxylin-eosin (H&E) and Masson staining revealed inflammatory cell infiltration and fibrous proliferation in the liver and small intestine tissue in the model group and partial cell swelling in the TAK-242 group, which indicated a considerable improvement compared to the model group. RT-qPCR, Western blot, and IHC data indicated that TAK-242 reduced the IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB expression in the liver and small intestine tissues of HF rats. Conclusion. TAK-242 might downregulate the TLR4/MyD88/NF-κB signal pathway through the liver-gut axis, suppress the inflammatory response, and eventually alleviate HF in rats.

Fluorofenidone Protects Liver Against Inflammation and Fibrosis by Blocking the Activation of NF‐κB Pathway

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Fluorofenidone Attenuates Inflammation by Inhibiting the NF-кB Pathway.

Fluorofenidone Affects Hepatic Stellate Cell Activation in Hepatic Fibrosis by Targeting the TGF-β1/Smad and MAPK Signaling Pathways.

Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy

Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway

Fluorofenidone Ameliorates Cholestasis and Fibrosis by Inhibiting Hepatic Erk/-Egr-1 Signaling and Tgfβ1/Smad Pathway in Mice.

Fluorofenidone Inhibits Macrophage IL-1β Production by Suppressing Inflammasome Activity

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway

Protective Effect of Fluorofenidone Against Acute Lung Injury Through Suppressing the MAPK/NF-κB Pathway

Protective Effect of Fluorofenidone Against Acute Lung Injury Through Suppressing the MAPK/NF-B Pathway

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-β1/Smad pathway: implications for liver cancer

Fluorofenidone is an Effective Drug for Cholestasis and Fibrosis in a Preclinical Study